After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
Stocks Info
As a NASDAQ listed company, ZYME falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Zymeworks BC Inc is $1.02B. A total of 0.48 million shares were traded on the day, compared to an average of 500.46K shares.
In the most recent transaction, EcoR1 Capital, LLC bought 101,659 shares of ZYME for 14.49 per share on Dec 27 ’24. After the transaction, the Director now owns 14,822,590 company shares. In a previous transaction on Dec 26 ’24, EcoR1 Capital, LLC bought 16,692 shares at 14.38 per share. ZYME shares that Director owns now total 14,720,931.
Among the insiders who bought shares, EcoR1 Capital, LLC acquired of 11,958 shares on Dec 24 ’24 at a per-share price of $14.12. This resulted in the Director holding 14,704,239 shares of ZYME after the transaction. In another insider transaction, Galbraith Kenneth sold 18,198 shares at $10.65 per share on Jan 05 ’24. Company shares held by the Chair & CEO now total 29,468.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, ZYME has a high of $17.70 and a low of $7.97.
As of this writing, ZYME has an earnings estimate of -$0.04 per share for the current quarter. EPS was calculated based on a consensus of 5.0 estimates, with a high estimate of $0.95 per share and a lower estimate of -$0.69.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. ZYME’s latest balance sheet shows that the firm has $252.61M in Cash & Short Term Investments as of fiscal 2021. There were $32.33M in debt and $71.85M in liabilities at the time. Its Book Value Per Share was $5.23, while its Total Shareholder’s Equity was $249.09M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ZYME is Buy with a score of 4.50.
